CN103476403A - 阿片样物质的控释制剂 - Google Patents

阿片样物质的控释制剂 Download PDF

Info

Publication number
CN103476403A
CN103476403A CN2011800562785A CN201180056278A CN103476403A CN 103476403 A CN103476403 A CN 103476403A CN 2011800562785 A CN2011800562785 A CN 2011800562785A CN 201180056278 A CN201180056278 A CN 201180056278A CN 103476403 A CN103476403 A CN 103476403A
Authority
CN
China
Prior art keywords
oxycodone
salt
opioid
pharmaceutical preparation
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800562785A
Other languages
English (en)
Chinese (zh)
Inventor
E·M·鲁德尼克
M·瓦尚
G·W·佩斯
J·贝里
F·D·L·伊格莱西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QRxPharma Ltd
Original Assignee
QRxPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/024,319 external-priority patent/US20110195989A1/en
Application filed by QRxPharma Ltd filed Critical QRxPharma Ltd
Publication of CN103476403A publication Critical patent/CN103476403A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800562785A 2010-09-24 2011-09-23 阿片样物质的控释制剂 Pending CN103476403A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38622710P 2010-09-24 2010-09-24
US61/386,227 2010-09-24
US13/024,319 2011-02-09
US13/024,319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids
PCT/US2011/053132 WO2012040651A2 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids

Publications (1)

Publication Number Publication Date
CN103476403A true CN103476403A (zh) 2013-12-25

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800562785A Pending CN103476403A (zh) 2010-09-24 2011-09-23 阿片样物质的控释制剂

Country Status (6)

Country Link
EP (1) EP2618820A2 (enExample)
JP (1) JP2013537915A (enExample)
CN (1) CN103476403A (enExample)
AU (1) AU2011305161A1 (enExample)
CA (1) CA2812570A1 (enExample)
WO (1) WO2012040651A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114515282A (zh) * 2020-11-19 2022-05-20 山东大学 Sorbic acid在制备抗冠状病毒感染药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
AU2013204592A1 (en) * 2012-04-09 2013-10-24 QRxPharma Ltd. Controlled release formulations of opioids
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
AU2015290098B2 (en) * 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CN101151021A (zh) * 2005-03-28 2008-03-26 奥瑞克索股份公司 用于疼痛治疗的新药物组合物
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药
US20090291975A1 (en) * 2008-05-20 2009-11-26 Warren Stern Dual opioid pain therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CA2593165A1 (en) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Analgesic conjugates
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
CN101151021A (zh) * 2005-03-28 2008-03-26 奥瑞克索股份公司 用于疼痛治疗的新药物组合物
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药
US20090291975A1 (en) * 2008-05-20 2009-11-26 Warren Stern Dual opioid pain therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARLA RIPAMONTI1.ET AL: "Strategies for the Treatment of Cancer", 《DRUGS》, vol. 61, no. 7, 31 December 2001 (2001-12-31), pages 955 - 977 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114515282A (zh) * 2020-11-19 2022-05-20 山东大学 Sorbic acid在制备抗冠状病毒感染药物中的应用
CN114515282B (zh) * 2020-11-19 2023-09-08 山东大学 Sorbic acid在制备抗冠状病毒感染药物中的应用

Also Published As

Publication number Publication date
EP2618820A2 (en) 2013-07-31
JP2013537915A (ja) 2013-10-07
AU2011305161A1 (en) 2013-05-09
WO2012040651A2 (en) 2012-03-29
WO2012040651A3 (en) 2012-05-18
CA2812570A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
CN103476403A (zh) 阿片样物质的控释制剂
JP5508722B2 (ja) 事故的誤用および不法転用を防止するための耐破砕性錠剤
US20110195989A1 (en) Controlled Release Formulations of Opioids
AU2008286914B2 (en) Abuse resistant drugs, method of use and method of making
JP6550157B2 (ja) Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
US20130022646A1 (en) Controlled Release Formulations of Opioids
AU2012347200B2 (en) Tablet capable of combatting misuse by injection
IL235150A (en) Pharmaceuticals
KR20190014577A (ko) 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
WO2013153451A2 (en) Controlled release formulations of opioids
AU2012202717B2 (en) Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
AU2018219999A1 (en) Pharmaceutical composition
HK1191570A (en) Pharmaceutical composition comprising opioid agonist and sequestered antagonist
HK1165263B (en) Crush–resistant tablets intended to prevent accidental misuse and unlawful diversion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131225